Insmed Incorporated announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE(R) (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.32 USD | +1.11% | +2.78% | -11.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.84% | 4.06B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.57% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |
- Stock
- Equities
- Stock Insmed Incorporated - Nasdaq
- News Insmed Incorporated
- Insmed Incorporated Names Drayton Wise as Chief Commercial Officer